Cover Image
Market Research Report

Investigation Report on China's Telmisartan Market, 2018-2022

Published by China Research and Intelligence Product code 296863
Published Content info 30 Pages
Delivery time: 1-2 business days
Price
Back to Top
Investigation Report on China's Telmisartan Market, 2018-2022
Published: December 13, 2018 Content info: 30 Pages
Description

By the end of 2017, there were about 330 million hypertensive patients in China, in another word, one in every three adults in China had hypertension. The incidence of hypertension in China rose from 5.1% in 1959 to 37.2% in 2017.

Angiotensin II receptor antagonists (angiotensin receptor blockers, ARBs) are antihypertensive drugs that has been growing rapidly since it emerged in the 1990s. As an important ARB administered orally once a day to treat essential hypertension,

Telmisartan was discovered by Boehringer Ingelheim and first launched in the U.S. as Micardis in 1999. In the same year, in Germany, it was launched by Boehringer Ingelheim and Glaxo Wellcome in the trades name of Micardis and Pritor respectively. Then it was marketed in several countries. The patent for Telmisartan expired in 2014.

At the end of 2000, Boehringer Ingelheim introduced the active pharmaceutical ingredient and preparations of Telmisartan to China. Telmisartan had developed fast since it entered in China. The sales value kept increasing before 2014 when it began to decrease, reaching about CNY 165 million in 2017. At present, China's Telmisartan market is dominated by Boehringer Ingelheim, China Resources Double-Crane Pharmaceutical Co., Ltd., Yichang HEC Changjiang Pharmaceutical Co., Ltd., and Jiangsu Wanbang Biopharmaceuticals Co., Ltd. Boehringer Ingelheim has the largest market share. In 2017, its market share by sales value was about 72.4% but showed a downward trend. It is expected that with the increasing number of hypertensive patients, China's Telmisartan market will still have some growth potential.

Topics Covered:

  • Sales of Telmisartan in China
  • Sales of Telmisartan in China by region
  • Competitive landscape of China's Telmisartan market
  • Prices of Telmisartan in China
  • Major factors affecting China's Telmisartan market
  • Prospect of China's Telmisartan market
Table of Contents
Product Code: 1812357

Table of Contents

1. Relevant Concepts of Telmisartan

  • 1.1. Indications for Telmisartan
  • 1.2. Development of Telmisartan in China
  • 1.3. Governmental Approval of Telmisartan in China

2. Sales of Telmisartan in China, 2013-2017

  • 2.1. Sales Value of Telmisartan
    • 2.1.1. Overall Sales Value
    • 2.1.2. Sales Value by Region
  • 2.2. Sales Volume of Telmisartan

2. 2.1. Overall Sales Volume

    • 2.2.2. Sales Volume by Region
  • 2.3. Sales of Telmisartan by Dosage Form in China, 2013-2017
    • 2.3.1. Tablets
    • 2.3.2. Capsules

3. Analysis on Major Telmisartan Manufacturers in China, 2013-2017

  • 3.1. Analysis on Market Share of Major Telmisartan Manufacturers
    • 3.1.1. Market Share by Sales Value
    • 3.1.2. Market Share by Sales Volume
  • 3.2. Boehringer Ingelheim
    • 3.2.1. Enterprise Profile
    • 3.2.2. Sales of Boehringer Ingelheim's Telmisartan in China
  • 3.3. China Resources Double-Crane Pharmaceutical Co., Ltd.
    • 3.3.1. Enterprise Profile
    • 3.3.2. Sales of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan in China
  • 3.4. Yichang HEC Changjiang Pharmaceutical Co., Ltd.
    • 3.4.1. Enterprise Profile
    • 3.4.2. Sales of Yichang HEC Changjiang Pharmaceutical Co., Ltd.'s Telmisartan in China
  • 3.5. Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
    • 3.5.1. Enterprise Profile
    • 3.5.2. Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Telmisartan in China
  • 3.6. Suzhou Dawnrays Pharmaceutical Co., Ltd.
    • 3.6.1. Enterprise Profile
    • 3.6.2. Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Telmisartan in China

4. Prices of Telmisartan in China, 2017-2018

  • 4.1. Boehringer Ingelheim (Micardis)
  • 4.2. China Resources Double-Crane Pharmaceutical Co., Ltd. (Suhe)
  • 4.3. Yichang HEC Changjiang Pharmaceutical Co., Ltd. (Oumeining)
  • 4.4. Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Bangtan)
  • 4.5. Suzhou Dawnrays Pharmaceutical Co., Ltd. (Anneiqiang)

5. Prospect of China's Telmisartan Market, 2018-2022

  • 5.1. Forecast on Market Size
  • 5.2. Forecast on Market Trend

Selected Charts:

  • Chart Governmental Approval of Telmisartan in China
  • Chart Sales of Telmisartan in China, 2013-2017
  • Chart Sales Value of Telmisartan in Parts of China, 2013-2017
  • Chart Sales Volume of Telmisartan in China, 2013-2017
  • Chart Sales Volume of Telmisartan in Parts of China, 2013-2017
  • Chart Sales Value of Telmisartan Tablets in China, 2013-2017
  • Chart Sales Volume of Telmisartan Tablets in China, 2013-2017
  • Chart Sales Value of Telmisartan Capsules in China, 2013-2017
  • Chart Market Share of Top 5 Telmisartan Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Telmisartan Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Boehringer Ingelheim's Telmisartan in China, 2013-2017
  • Chart Sales Volume of Boehringer Ingelheim's Telmisartan in China, 2013-2017
  • Chart Sales Value of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan, 2013-2017
  • Chart Sales Volume of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan, 2013-2017
  • Chart Sales Value of Yichang HEC Changjiang Pharmaceutical Co., Ltd. 's Telmisartan, 2013-2017
  • Chart Sales Value of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Telmisartan, 2013-2017
  • Chart Prices of Boehringer Ingelheim's Telmisartan in Parts of China, 2017-2018
  • Chart Prices of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan in Parts of China, 2017-2018
  • Chart Prices of Yichang HEC Changjiang Pharmaceutical Co., Ltd.'s Telmisartan in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Telmisartan in China, 2018-2022
Back to Top